SRZN vs YDES
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
SRZN exhibits critical financial instability, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is operating with negative equity (Price/Book: -1.64) and an unsustainable Price/Sales ratio of 106.77, suggesting the current valuation is entirely speculative. While the current ratio of 9.22 provides a temporary liquidity cushion, the combination of declining revenue (-19.4% YoY) and massive earnings misses (most recent surprise -678.8%) points to a failing operational model. The recent price surge is disconnected from all deterministic health and value metrics.
YDES exhibits severe financial instability characterized by a weak Piotroski F-Score of 3/9 and a catastrophic technical trend. While the company maintains a pristine balance sheet with zero debt and an exceptional current ratio of 13.18, these are offset by an absurd Price-to-Sales ratio of 724.75 and deeply negative operating margins (-444.59%). The stock is currently in a freefall, trading near its 52-week low after a 60.7% one-year decline, suggesting a massive loss of investor confidence despite high year-over-year revenue growth.
Compare Another Pair
Related Comparisons
SRZN vs YDES: Head-to-Head Comparison
This page compares Surrozen, Inc. (SRZN) and YD Bio Ltd (YDES) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.